Kamstrup, Maria Rørbæk2; Biskup, Edyta2; Gjerdrum, Lise Mette Rahbek3; Ralfkiaer, Elizabeth2; Niazi, Omid2; Gniadecki, Robert2
1 Department of Clinical Medicine, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Københavns Universitet2 unknown3 Department of Clinical Medicine, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Københavns Universitet
Peripheral T-cell lymphomas (PTLs) represent an area of high medical need. Previously, we demonstrated high expression of Notch, a known oncogene, in primary cutaneous anaplastic large cell lymphoma (ALCL). In this study, we performed immunohistochemical staining for Notch1 in lymph nodes from PTL not otherwise specified (PTL-NOS) and systemic ALCL (ALK+ and ALK-) and report a similar distribution among the three subgroups: Negative, moderate and strong expression was, respectively, 18%, 27% and 55% for PTL-NOS (33 cases), 20%, 0% and 80% for ALCL ALK+ (10 cases) and 45%, 22% and 33% for ALCL ALK- (nine cases) (p > 0.05). In the ALK+ ALCL cell line, Karpas-299, pharmacological inhibition of Notch with γ-secretase inhibitor (GSI) I was far more potent than with GSI IX, XX and XXI with regard to cell viability and apoptosis. In conclusion, PTL tumor cells have prominent Notch1 expression and treatment with Notch inhibitors has cytotoxic effects.
Leukemia and Lymphoma, 2014, Vol 55, Issue 3, p. 639-644
Adolescent; Adult; Aged; Aged, 80 and over; Amyloid Precursor Protein Secretases; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Child; Child, Preschool; Female; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Oligopeptides; Receptor, Notch1; Receptors, Notch; Signal Transduction; Young Adult